Moreover, more suitable senolysis compounds should be explored for clinical applications of p16INK4a-targeted senotherapy in T2DM due to clinical intolerability, and they are seemingly less effective in HFD models with chronic insulin resistance of ABT263 (36, 37). This evidence concerns the gene CDKN2A and type 2 diabetes mellitus.